QT Imaging (NASDAQ:QTI – Get Free Report) and TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, profitability, institutional ownership and dividends.
Earnings & Valuation
This table compares QT Imaging and TriSalus Life Sciences”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| QT Imaging | $18.92 million | 1.90 | -$21.08 million | ($1.57) | -1.67 |
| TriSalus Life Sciences | $45.15 million | 6.19 | -$39.23 million | ($1.30) | -3.49 |
Profitability
This table compares QT Imaging and TriSalus Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| QT Imaging | -77.25% | -1,202.69% | -46.76% |
| TriSalus Life Sciences | -62.59% | N/A | -64.47% |
Insider & Institutional Ownership
24.2% of QT Imaging shares are held by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are held by institutional investors. 25.4% of QT Imaging shares are held by insiders. Comparatively, 16.3% of TriSalus Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of recent ratings and price targets for QT Imaging and TriSalus Life Sciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| QT Imaging | 1 | 1 | 1 | 0 | 2.00 |
| TriSalus Life Sciences | 1 | 1 | 3 | 0 | 2.40 |
TriSalus Life Sciences has a consensus price target of $10.20, indicating a potential upside of 124.92%. Given TriSalus Life Sciences’ stronger consensus rating and higher possible upside, analysts clearly believe TriSalus Life Sciences is more favorable than QT Imaging.
Summary
TriSalus Life Sciences beats QT Imaging on 8 of the 13 factors compared between the two stocks.
About QT Imaging
QT Imaging Holdings, Inc. engages in the research, development, and commercialization of body imaging systems for detection, diagnosis, monitoring, and treatment of diseases. The company offers QT Ultrasound Breast Scanner, an ultrasonic imaging system that provides reflection-mode and transmission-mode images of a patient’s breast. QT Imaging Holdings, Inc. was founded in 2011 and is based in Novato, California.
About TriSalus Life Sciences
TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.
Receive News & Ratings for QT Imaging Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for QT Imaging and related companies with MarketBeat.com's FREE daily email newsletter.
